Q2 2026 saw 10% revenue growth and 21% higher adjusted EBITDA, led by blockbuster products and strong U.S. segment performance. Full-year guidance was raised across revenue, EBITDA, and EPS, with improved leverage and continued innovation investment.Original document: Elanco Animal Health Incorpora…
Q2 2026 saw 10% revenue growth and 21% higher adjusted EBITDA, led by blockbuster products and strong U.S. segment performance. Full-year guidance was raised across revenue, EBITDA, and EPS, with improved leverage and continued innovation investment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.